PA8853801A1 - Composición de liberación pulsátil de sildenafil y proceso para prepararla - Google Patents

Composición de liberación pulsátil de sildenafil y proceso para prepararla

Info

Publication number
PA8853801A1
PA8853801A1 PA20098853801A PA8853801A PA8853801A1 PA 8853801 A1 PA8853801 A1 PA 8853801A1 PA 20098853801 A PA20098853801 A PA 20098853801A PA 8853801 A PA8853801 A PA 8853801A PA 8853801 A1 PA8853801 A1 PA 8853801A1
Authority
PA
Panama
Prior art keywords
sildenafil
release
pulsatable
prepare
release composition
Prior art date
Application number
PA20098853801A
Other languages
English (en)
Inventor
Alejandro Fiore Esteban
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42242382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8853801(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of PA8853801A1 publication Critical patent/PA8853801A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA DE SILDENAFIL DE LIBERACIÓN PULSÁTIL QUE COMPRENDE UNA FRACCIÓN DE LIBERACIÓN INMEDIATA QUE CONTIENE 5 A 100 MG DE SILDENAFIL Y UNA FRACCIÓN DE LIBERACIÓN CONTROLADA QUE CONTIENE 25 A 150 MG DE SILDENAFIL, EN DONDE LA FRACCIÓN DE LIBERACIÓN CONTROLADA ESTÁ COMPUESTA POR PARTÍCULAS QUE CONTIENEN (A) UN AGENTE SUPERDESINTEGRANTE, (B) UN RECUBRIMIENTO FORMADO POR AL MENOS UN POLÍMERO DE SOLUBILIDAD PH-DEPENDIENTE Y AL MENOS UN POLÍMERO DE SOLUBILIDAD PH-INDEPENDIENTE Y (C) OPCIONALMENTE OTROS EXCIPIENTES FARMACÉUTICOS. LA COMPOSICIÓN DE LA PRESENTE INVENCIÓN PRESENTA UN PERFIL DE DISOLUCIÓN MÁS RÁPIDO EN MEDIO ALCALINO QUE EN MEDIO ÁCIDO, LO QUE PERMITE OBTENER FORMULACIONES MEJORADAS DE LIBERACIÓN PULSÁTIL.
PA20098853801A 2008-12-12 2009-12-11 Composición de liberación pulsátil de sildenafil y proceso para prepararla PA8853801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/003466 WO2010067140A1 (es) 2008-12-12 2008-12-12 Composicion de liberacion pulsatil de sildenafil y proceso para prepararla

Publications (1)

Publication Number Publication Date
PA8853801A1 true PA8853801A1 (es) 2010-07-27

Family

ID=42242382

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098853801A PA8853801A1 (es) 2008-12-12 2009-12-11 Composición de liberación pulsátil de sildenafil y proceso para prepararla

Country Status (13)

Country Link
US (1) US20110244050A1 (es)
EP (1) EP2374460A4 (es)
AR (1) AR071970A1 (es)
BR (1) BRPI0823356A2 (es)
CL (1) CL2009002173A1 (es)
CR (1) CR20110322A (es)
EC (1) ECSP11011194A (es)
MX (1) MX339136B (es)
NI (1) NI201100119A (es)
PA (1) PA8853801A1 (es)
PE (1) PE20100471A1 (es)
UY (1) UY32304A (es)
WO (1) WO2010067140A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498441B2 (en) 2012-01-27 2016-11-22 Siegfried Rhein S.A. De C.V. Nitazoxadine composition and process to prepare same
EA019381B1 (ru) * 2012-07-20 2014-03-31 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Таблетка, содержащая ингибитор фосфодиэстеразы пятого типа, способ ее получения и ее применение
KR101340733B1 (ko) * 2012-12-31 2013-12-12 (주) 에프엔지리서치 신규한 마이크로그래뉼 제형
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
WO2017168174A1 (en) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2023037394A1 (en) * 2021-09-13 2023-03-16 Amman Pharmaceutical Industries Company A pharmaceutical composition of sildenafil and a formulation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
TR199901564T2 (xx) 1997-01-06 1999-09-21 Pfizer Inc. H�zl� ��z�lebilen ve tat-maskesi sa�layan dozaj ispen�iyari formu.
CA2235642C (en) 1998-05-15 2007-11-13 Torcan Chemical Ltd. Processes for preparing sildenafil
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
CA2440588C (en) * 2001-03-13 2010-02-09 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US8512751B2 (en) * 2004-12-20 2013-08-20 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
KR20140114887A (ko) * 2006-08-31 2014-09-29 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물의 고용체를 포함하는 약물 전달 시스템

Also Published As

Publication number Publication date
NI201100119A (es) 2012-08-03
MX339136B (es) 2016-05-13
PE20100471A1 (es) 2010-07-22
EP2374460A4 (en) 2013-08-21
MX2011005752A (es) 2011-08-12
WO2010067140A1 (es) 2010-06-17
UY32304A (es) 2010-05-31
CR20110322A (es) 2011-10-25
EP2374460A1 (en) 2011-10-12
BRPI0823356A2 (pt) 2015-06-16
ECSP11011194A (es) 2011-09-30
AR071970A1 (es) 2010-07-28
US20110244050A1 (en) 2011-10-06
CL2009002173A1 (es) 2010-04-09

Similar Documents

Publication Publication Date Title
PA8853801A1 (es) Composición de liberación pulsátil de sildenafil y proceso para prepararla
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
AR054114A1 (es) Composiciones farmaceuticas que comprenden imatinib y un retardador de la liberacion
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
ECSP099577A (es) Formulaciones para el tratamiento del cáncer
AR050717A1 (es) Composiciones farmaceuticas
BR112018001534A2 (pt) inibidor de isocitrato desidrogenase idh1 r132h mutante
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
BR112015011430A2 (pt) composição para liberação imediata e prolongada
AR070964A1 (es) Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento
MX2016014771A (es) Forma de dosificacion oralmente desintegrante para administracion de avanafil, y metodos de fabricacion y uso asociados.
CU20090200A7 (es) Una composición de liberación prolongada que comprende un derivado de somatostatina en micropartículas
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
MA38646A1 (fr) Formulation a liberation modifiee pour traiter, par ex. La maladie de parkinson et la dyskinesie induite par l-dopa.
ECSP11011286A (es) Formulaciones orales sólidas de una pirido-pirimidinona
BR112014032583A2 (pt) forma farmacêutica para liberação prolongada de substâncias ativas
AR075041A1 (es) Composicion farmaceutica que contiene aleglitazar, proceso, uso.
UY29989A1 (es) Composiciones farmacéuticas de agentes hipnoticos de accion corta en forma de liberación modificada y los procedimientos para preparar dichas formulaciones
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
CO6390108A2 (es) Composición de liberación pulsatil de sildenafil y proceso para prepararla
DOP2011000181A (es) Composicion de liberacion pulsatil de sildenafil y proceso para prepararla
GT201100159A (es) Composicion de liberación pulsatil de sildenafil y proceso para prepararla
FR3058060B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
CO6331424A2 (es) Formulacion farmaceutica de eprosartan